Real‐world rates, predictors and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: Results of a pooled analysis of six retrospective observational studies

Abstract Authors: Xie L, Wei W, Pan C, Baser O. Objective: To evaluate the real-world rates of hypoglycemia and related costs among patients with type 2 diabetes mellitus (T2DM) who initiated insulin glargine with either a disposable pen or vial-and-syringe....

Comparison of real‐world adherence, health care resource utilization and costs for newly initiated valsartan/amlodipine single‐pill combination vs angiotensin‐receptor blocker/calcium‐channel blocker free combination therapy

Abstract Authors: Baser O, Andrews LM, Wang L, Xie L. Objective: To compare adherence, healthcare costs and utilization of valsartan/amlodipine single-pill combination (SPC) and angiotensin-receptor blocker/calcium-channel blocker multiple-pill free-combination...